Nearly half of patients with high-risk localized prostate cancer who undergo radical prostatectomy eventually see their cancer return — and for decades, the surgical window has closed before any systemic agent entered the picture. PROTEUS, a 2,109-patient Phase 3 trial, puts a hard number on what earlier intervention can do: patients receiving apalutamide plus androgen deprivation therapy for six months before and after surgery were nine times more likely to achieve pathologic complete response or minimal residual disease at the time of surgery compared with ADT alone (8.9% vs. 1.0%, OR 10.17).
The dual-primary design was deliberately ambitious. Pathologic response at surgery and metastasis-free survival are not surrogate cousins — they measure fundamentally different things at fundamentally different timepoints. Both endpoints cleared statistical significance. The 20% reduction in metastasis or death (HR 0.80) is modest in relative terms, but the downstream consequence is not: patients on the combination arm went more than six years before needing subsequent therapy versus roughly three and a half years on ADT alone (74.2 vs. 41.5 months, HR 0.65). That gap represents a meaningful compression of the treatment escalation ladder — fewer salvage regimens, lower cumulative toxicity burden, and a longer interval before patients enter the metastatic treatment economy entirely. Testosterone recovery occurred within a median of 8.1 months, addressing the concern that prolonged ADT exposure would leave patients with sustained hormonal suppression after a curative-intent procedure.
The trial’s plenary slot at ASCO and simultaneous NEJM publication signal that the oncology community already regards this as practice-forming rather than hypothesis-generating. The perioperative space — neoadjuvant plus adjuvant wrapped around surgery — has been stubbornly resistant in prostate cancer. Docetaxel tried and failed here. Apalutamide’s androgen receptor pathway mechanism appears better matched to the biology of high-risk localized disease than cytotoxics ever were. The event-free survival reduction of 29% (HR 0.71) and time-to-distant-metastasis improvement (HR 0.68) add further layering that makes the MFS result difficult to dismiss as a marginal benefit in a heavily censored dataset.
The single number worth watching in the months ahead is overall survival. PROTEUS has not yet reported mature OS data, and that result will determine whether the paradigm shift this trial claims is durable enough to rewrite guideline language from “consider” to “recommend.”
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
